Prospects for the world market and submarkets for those follow-on biologics
Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of seven biosimilar mAb submarkets:• Infliximab• Rituximab• Adalimumab• Trastuzumab• Bevacizumab• Abciximab• Other molecules (grouped analysis).
How will the biosimilar mAbs market expand? Which parts will most prosper? There you assess prospects for revenue growth.
Our study gives you a feel for what stimulates and restrains that industry and market. That analysis helps you identify potential and find ways for your business to develop.
You also find revenue predictions for products using follow-on antibody technology.
Forecasts for 13 agents - assess potential of existing and expected products How will products perform to 2023 at world level? Our report forecasts individual revenues of 13 biosimilar antibodies, launched or in development, including these:
• Celltrion's Remsima
• Dr. Reddy's Reditux
• Epirus Biopharmaceuticals' BOW-015
• Boehringer Ingelheim's BI695500 and BI695501
• Fujifilm Kyowa Kirin Biologics' forms of adalimumab and bevacizumab
• Biocon's Bmab200
• BIOCAD's BCD-022
• Isu Abxis's Clotinab
• Reliance Life Sciences' R-TPR-019.
There you discover how high sales can go, to 2023, finding products and years with highest predicted growth and revenues. Also you compare competitors. You see what's happening, then, understanding trends, competition, challenges, and opportunities.
Our investigation also divides its overall world forecast into geographical regions.
National markets - what outlooks for sales? Developments worldwide expand the biosimilar mAbs market. Hear about the best revenue prospects.
Copyright©2012 PR Newswire.
All rights reserved